WO2002046227A3 - Glp-1 fusion proteins - Google Patents
Glp-1 fusion proteins Download PDFInfo
- Publication number
- WO2002046227A3 WO2002046227A3 PCT/US2001/043165 US0143165W WO0246227A3 WO 2002046227 A3 WO2002046227 A3 WO 2002046227A3 US 0143165 W US0143165 W US 0143165W WO 0246227 A3 WO0246227 A3 WO 0246227A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion proteins
- glp
- proteins
- glucagon
- peptides
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200300644A EA005584B1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
CA2434237A CA2434237C (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
MXPA03005036A MXPA03005036A (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins. |
EP01995845A EP1355942B1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
HU1300326A HU230603B1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
AU2689702A AU2689702A (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
DK06118975T DK1724284T3 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
SI200130878T SI1355942T1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
US10/433,108 US7271149B2 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
JP2002547963A JP2004528014A (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion protein |
DK01995845T DK1355942T3 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
SK50057-2011A SK288088B6 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
BR0116024-9A BR0116024A (en) | 2000-12-07 | 2001-11-29 | Heterologous Fusion Protein and Use thereof |
IL15581201A IL155812A0 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
AU2002226897A AU2002226897B2 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
SK670-2003A SK288342B6 (en) | 2000-12-07 | 2001-11-29 | GLP-1 fusion proteins |
KR1020037007541A KR100942864B1 (en) | 2000-12-07 | 2001-11-29 | GLP-1 Fusion Proteins |
PL366208A PL209550B1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
HU0302529A HU229218B1 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
NZ525577A NZ525577A (en) | 2000-12-07 | 2001-11-29 | Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus |
UA2003065280A UA81897C2 (en) | 2000-12-07 | 2001-11-29 | Normal;heading 1;heading 2;GLUCAGON-LIKE PEPTIDE 1 HETEROLOGOUS FUSION PROTEIN FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS |
DE60135581T DE60135581D1 (en) | 2000-12-07 | 2001-11-29 | GLP-1 FUSION PROTEINS |
IL155812A IL155812A (en) | 2000-12-07 | 2003-05-08 | Glp-1 fusion proteins |
NO20032565A NO331273B1 (en) | 2000-12-07 | 2003-06-05 | GLP-1 fusion proteins and their applications. |
HR20030455A HRP20030455A2 (en) | 2000-12-07 | 2003-06-05 | Glp-1 fusion proteins |
HK04102243.7A HK1061411A1 (en) | 2000-12-07 | 2004-03-25 | Glp-1 fusion proteins |
IL184429A IL184429A (en) | 2000-12-07 | 2007-07-05 | Heterologous fusion proteins comprising a glp-1 compound fused to another polypeptide, pharmaceutical formulations comprising them and use thereof in the preparation of medicaments |
NO20101602A NO20101602L (en) | 2000-12-07 | 2010-11-15 | GLP-1 fusion proteins |
NO20111369A NO332221B1 (en) | 2000-12-07 | 2011-10-10 | GLP-1 fusion proteins and their use in the preparation of drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25195400P | 2000-12-07 | 2000-12-07 | |
US60/251,954 | 2000-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002046227A2 WO2002046227A2 (en) | 2002-06-13 |
WO2002046227A3 true WO2002046227A3 (en) | 2003-04-24 |
Family
ID=22954069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/043165 WO2002046227A2 (en) | 2000-12-07 | 2001-11-29 | Glp-1 fusion proteins |
Country Status (30)
Country | Link |
---|---|
US (1) | US7271149B2 (en) |
EP (2) | EP1355942B1 (en) |
JP (2) | JP2004528014A (en) |
KR (2) | KR100942864B1 (en) |
CN (2) | CN1483041A (en) |
AT (2) | ATE437891T1 (en) |
AU (2) | AU2002226897B2 (en) |
BR (1) | BR0116024A (en) |
CA (2) | CA2434237C (en) |
CY (2) | CY1108485T1 (en) |
CZ (2) | CZ308214B6 (en) |
DE (2) | DE60139430D1 (en) |
DK (2) | DK1355942T3 (en) |
EA (1) | EA005584B1 (en) |
EC (1) | ECSP064643A (en) |
ES (2) | ES2311560T3 (en) |
HK (1) | HK1061411A1 (en) |
HR (1) | HRP20030455A2 (en) |
HU (2) | HU230603B1 (en) |
IL (3) | IL155812A0 (en) |
MX (1) | MXPA03005036A (en) |
NO (3) | NO331273B1 (en) |
NZ (1) | NZ525577A (en) |
PL (2) | PL393178A1 (en) |
PT (2) | PT1724284E (en) |
SI (2) | SI1355942T1 (en) |
SK (2) | SK288088B6 (en) |
UA (2) | UA93662C2 (en) |
WO (1) | WO2002046227A2 (en) |
ZA (1) | ZA200303642B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9173950B2 (en) | 2012-05-17 | 2015-11-03 | Extend Biosciences, Inc. | Vitamin D-ghrelin conjugates |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
Families Citing this family (317)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
HU229108B1 (en) * | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7427665B2 (en) | 2000-12-08 | 2008-09-23 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP1351984A2 (en) * | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
EP2275117B1 (en) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
HUP0501192A3 (en) * | 2001-08-23 | 2006-06-28 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
HUP0700151A2 (en) * | 2001-10-18 | 2007-05-29 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
WO2003059934A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
AU2003200839B2 (en) * | 2002-01-08 | 2008-12-11 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
DE60331226D1 (en) | 2002-05-24 | 2010-03-25 | Medtronic Inc | METHOD AND DNA CONSTRUCTIONS FOR PRODUCING POLYPEPTIDES HAVING HIGH PROFIT |
WO2004002417A2 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
CN1713920A (en) * | 2002-08-30 | 2005-12-28 | 比奥雷克西斯药物公司 | Modified transferrin fusion proteins |
EP1569682A2 (en) * | 2002-12-03 | 2005-09-07 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
EP1688148A1 (en) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
JP3974619B2 (en) * | 2003-01-10 | 2007-09-12 | 株式会社新潟ティーエルオー | Gene therapy vector and method for quantifying target protein in mammals or cultured cells to which the gene therapy vector is administered |
WO2004069862A1 (en) * | 2003-02-06 | 2004-08-19 | Keio University | Peptide conjugate |
MXPA05009940A (en) * | 2003-03-19 | 2005-12-05 | Lilly Co Eli | Polyethelene glycol link glp-1 compounds. |
KR101198346B1 (en) | 2003-04-08 | 2012-11-06 | 노보 노르디스크 에이/에스 | Regeneration of chromatographic stationary phases |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
ATE549028T1 (en) | 2003-05-15 | 2012-03-15 | Tufts College | STABLE ANALOGUES OF GLP-1 |
DK1641483T3 (en) * | 2003-06-12 | 2008-06-02 | Lilly Co Eli | Fusion Proteins |
EA008831B1 (en) * | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Glp-1 analog fusion proteins |
TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
EP2932981B1 (en) * | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
ES2372495T3 (en) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | METHOD FOR MASS PRODUCTION OF THE CONSTANT REGION OF IMMUNOGLOBULIN. |
KR101135244B1 (en) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
DK1687019T3 (en) | 2003-11-20 | 2018-02-12 | Novo Nordisk As | Propylene glycol peptide formulations that are optimal for production and use in injection devices |
JP4865565B2 (en) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Controlling food selection using GLP-1 agonists |
CA2550050A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
US20060252693A1 (en) * | 2004-01-29 | 2006-11-09 | Wolfgang Glaesner | Glucagon-like peptide-1 analogs |
CN1980687B (en) * | 2004-02-09 | 2015-05-13 | 人类基因科学公司 | Albumin fusion proteins |
EP1729795B1 (en) * | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP5638177B2 (en) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | Pancreatic polypeptide family motif and polypeptide containing the motif |
KR20120034237A (en) * | 2004-02-11 | 2012-04-10 | 아밀린 파마슈티칼스, 인크. | Hybrid polypeptides with selectable properties |
US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
MXPA06011425A (en) * | 2004-03-31 | 2007-03-12 | Johnson & Johnson | Human glp-1 mimetibodies, compositions, methods and uses. |
SI3404102T1 (en) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
SI1751184T1 (en) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fusion proteins |
WO2005120492A1 (en) | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
WO2006037811A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted exendin-4 compounds |
JP5185624B2 (en) * | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | Bispecific antibodies targeting serum albumin and GLP-1 or PYY |
EP2168982A1 (en) * | 2004-12-22 | 2010-03-31 | Eli Lilly & Company | GLP-1 analog fusion protein formulations |
EP1843788A4 (en) * | 2004-12-22 | 2009-11-18 | Centocor Ortho Biotech Inc | Glp-1 agonists, compositions, methods and uses |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
KR20070120112A (en) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | Extended glp-1 compounds |
CN101389346A (en) * | 2005-03-28 | 2009-03-18 | 森托科尔公司 | Human glp-1 mimetibodies, compositions, methods and uses |
PT2650020T (en) * | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Trimeric ox40-immunoglobulin fusion protein and methods of use |
AU2006247734B2 (en) * | 2005-05-13 | 2011-06-23 | Eli Lilly And Company | GLP-1 pegylated compounds |
US8658174B2 (en) | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
US20090175795A1 (en) * | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
EP1924293A4 (en) * | 2005-08-06 | 2008-12-24 | Qinghua Wang | Composition and method for prevention and treatment of type i diabetes |
MX2008002028A (en) * | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties. |
EP2330124B1 (en) * | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
DK1767545T3 (en) * | 2005-09-22 | 2010-03-15 | Biocompatibles Uk Ltd | GLP-1 (Glucagon-like Peptide-1) Fusion Polypeptides with Increased Peptidase Resistance |
WO2007049695A1 (en) * | 2005-10-26 | 2007-05-03 | Chugai Seiyaku Kabushiki Kaisha | Agglutinable glp-1 analogue and sustained-release pharmaceutical composition |
LT1965823T (en) * | 2005-11-04 | 2016-10-10 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
CN1962695B (en) * | 2005-11-09 | 2011-08-31 | 浙江德清安平生物制药有限公司 | GLP-1 infusion proteins, their preparation and use |
US20080280328A1 (en) * | 2005-11-18 | 2008-11-13 | Novozymes A/S | Glucoamylase Variants |
EP1961764B1 (en) * | 2005-11-30 | 2011-05-11 | Shionogi Co., Ltd. | Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
DK2463305T3 (en) * | 2006-01-12 | 2016-08-29 | Alexion Pharma Inc | Antibodies to OX-2 / CD200 and uses thereof |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2007092252A2 (en) * | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
CN101003574B (en) * | 2006-02-21 | 2010-12-15 | 大连帝恩生物工程有限公司 | Recombined expression of peptide for lowering blood sugar in long acting, and application in medication for treating diabetes |
ES2495741T3 (en) | 2006-04-20 | 2014-09-17 | Amgen, Inc | GLP-1 Compounds |
EP1854455B1 (en) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Spherical microcapsules comprising GLP-1 peptides, their production and use |
EP2636680A3 (en) | 2006-05-26 | 2013-12-11 | Amylin Pharmaceuticals, LLC | Composition and methods for treatment of congestive heart failure |
CA2654055A1 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MX2009000748A (en) | 2006-07-18 | 2009-03-31 | Centocor Inc | Human glp-1 mimetibodies, compositions, methods and uses. |
ATE524493T1 (en) * | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | EXENDIN FUSION PROTEINS |
MX2009001691A (en) | 2006-08-31 | 2009-02-25 | Hoffmann La Roche | Method for the production of insulin-like growth factor-i. |
CL2007002502A1 (en) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE. |
CN103230598A (en) * | 2006-09-06 | 2013-08-07 | 费斯生物制药公司 | Fusion peptide therapeutic compositions |
JO2945B1 (en) * | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods For Administering Long-lasting Hypoglycemic Agents. |
TWI428346B (en) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
AU2011254001B2 (en) * | 2007-01-05 | 2012-08-02 | Covx Technologies Ireland Limited | Glucagon-like protein-1 receptor (GLP-1R) agonist compounds |
JP2008169195A (en) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | Insulinotopic peptide drug combo using carrier material |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
CN105688191A (en) | 2007-04-23 | 2016-06-22 | 精达制药公司 | Suspension formulations of insulinotropic peptides and uses thereof |
JP2009019027A (en) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | Insulin secretion peptide derivative in which amino acid of amino terminal is varied |
US8986684B2 (en) | 2007-07-25 | 2015-03-24 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
ES2672770T3 (en) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivatives of glucagon-like peptide-1 and its pharmaceutical use |
CN101842109B (en) | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | Peptides derivatized with A-B-C-D- and their therapeutical use |
JP2010538049A (en) * | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー/エス | Cleaved GLP-1 derivatives and therapeutic uses thereof |
CN108129573B (en) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | Targeted interferons exhibit potent apoptotic and antitumor activity |
US20090181037A1 (en) * | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
MX2010010776A (en) | 2008-03-31 | 2010-10-26 | Glaxo Group Ltd | Drug fusions and conjugates. |
BRPI0911266A2 (en) * | 2008-04-03 | 2015-09-29 | Hoffmann La Roche | pegylated insulin-like growth factor assay |
CN101328221B (en) * | 2008-04-14 | 2011-03-23 | 中国药科大学 | Hypoglycemic polypeptide fused protein, structure and use of derivate thereof |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | Therapeutic agents comprising elastin-like peptides |
JP5563572B2 (en) | 2008-07-23 | 2014-07-30 | ハンミ サイエンス カンパニー リミテッド | Bioactive polypeptide drug conjugates using non-peptidic polymers with tri-terminal functional groups |
US8865868B2 (en) | 2008-08-06 | 2014-10-21 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy |
US20100075897A1 (en) * | 2008-09-23 | 2010-03-25 | Jinan University | Method for sustainedly releasing bioactive peptides and application thereof |
RU2011118056A (en) | 2008-10-15 | 2012-11-27 | Ангиокем Инк. | GLP-1 AGONIC CONJUGATES AND THEIR APPLICATION |
CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
CN102307897B (en) | 2008-12-05 | 2016-01-20 | 葛兰素集团有限公司 | Select the method for protease resistant polypeptide |
PT2373681T (en) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Pharmaceutical compositions of albiglutide |
RU2539797C2 (en) | 2009-01-22 | 2015-01-27 | Ново Нордиск Хелс Кеа Аг | Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition |
CN106986933A (en) | 2009-02-11 | 2017-07-28 | 阿尔布梅迪克斯医疗公司 | Albumin variants and conjugate |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
MA33221B1 (en) | 2009-03-27 | 2012-04-02 | Glaxo Group Ltd | Integration of medicines and facilities |
CN102510759A (en) | 2009-04-20 | 2012-06-20 | 安吉奥开米公司 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
JP5932642B2 (en) | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | Multimeric peptide conjugates and uses thereof |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
EP2461831B1 (en) | 2009-08-06 | 2018-11-21 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
ES2870914T3 (en) * | 2009-08-14 | 2021-10-28 | Phasebio Pharmaceuticals Inc | Modified vasoactive intestinal peptides |
CN101993485B (en) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof |
CN101993496B (en) * | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | Dual blood sugar and blood fat adjusting fusion protein and preparation method and application thereof |
EA201290123A1 (en) | 2009-09-30 | 2012-10-30 | Глаксо Груп Лимитед | PRODUCTS OF MERGERS AND CONJUGATES OF MEDICINES WITH INCREASED PERIOD OF SEMI-EXTRACT |
KR101229610B1 (en) * | 2009-10-09 | 2013-02-05 | 한남대학교 산학협력단 | Fusion molecule of GLP-1 analogue, and composition comprising the same for preventing or treating diabetes mellitus |
CN102725312B (en) * | 2009-10-20 | 2014-10-01 | 佐治亚州立大学研究基金会公司 | Protein agent for diabetes treatment and beta cell imaging |
RU2607374C2 (en) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Versions of albumin |
CN102070717B (en) * | 2009-11-19 | 2013-04-10 | 东莞太力生物工程有限公司 | Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition |
EP2509616A4 (en) | 2009-12-08 | 2013-05-29 | Teva Pharma | Bche albumin fusions for the treatment of ***e abuse |
US9695226B2 (en) | 2010-01-22 | 2017-07-04 | Novo Nordisk Healthcare Ag | Growth hormones with prolonged in-vivo efficacy |
US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
AR081066A1 (en) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
KR20130070576A (en) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | Albumin derivatives and variants |
CN101875700B (en) * | 2010-04-09 | 2012-09-26 | 无锡和邦生物科技有限公司 | Method for improving bioactivity of exendin fusion protein |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
RU2012151296A (en) | 2010-04-30 | 2014-06-10 | Санва Кагаку Кенкюсо Ко., Лтд | A PEPTIDE FOR IMPROVING THE BIO-STABILITY OF A BIOACTIVE SUBSTANCE AND A BIOACTIVE SUBSTANCE HAVING AN INCREASED BIO-STABILITY |
JP2013525491A (en) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
WO2011153642A1 (en) * | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
CN101891823B (en) * | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | Exendin-4 and analog fusion protein thereof |
WO2011162830A2 (en) * | 2010-06-24 | 2011-12-29 | Biousian Biosystems, Inc. | Glucagon-like peptide-1 glycopeptides |
AU2011274229A1 (en) | 2010-07-02 | 2013-01-10 | Angiochem Inc. | Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
CN102311501A (en) * | 2010-07-08 | 2012-01-11 | 天津药物研究院 | Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof |
CN101906158B (en) * | 2010-07-14 | 2013-10-23 | 中国药科大学 | Pegylation hypoglycemic polypeptide and preparation method and application thereof |
KR101382593B1 (en) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity |
CN102532323B (en) * | 2010-12-09 | 2014-07-23 | 天津药物研究院 | Polypeptide complex, pharmaceutical composition, as well as preparation method and application of polypeptide complex |
RU2600440C3 (en) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT |
CN102533655A (en) * | 2010-12-21 | 2012-07-04 | 青岛黄海制药有限责任公司 | CHO-S cell strain for efficient expression type human recombinant protein GLP1/Fc and establishment method thereof |
WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
KR101969526B1 (en) | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | Medicinal agent for inhibiting metastasis of malignant tumor |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
WO2012136792A2 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Cck compositions |
WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
JP2014523900A (en) | 2011-06-28 | 2014-09-18 | インヒブルクス リミティド ライアビリティ カンパニー | Serpin fusion polypeptide and method of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
AU2012275295B2 (en) | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
EP2726502A1 (en) | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
AU2012283235A1 (en) | 2011-07-08 | 2014-01-09 | Bayer Intellectual Property Gmbh | Fusion proteins releasing Relaxin and uses thereof |
WO2013027680A1 (en) | 2011-08-19 | 2013-02-28 | 独立行政法人国立循環器病研究センター | Drug for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor gc-a agonist and gc-b agonist |
JP6118251B2 (en) * | 2011-08-25 | 2017-04-19 | 株式会社Lsiメディエンス | Method for measuring glucagon-like peptide-1 and kit used therefor |
CN104039822A (en) | 2011-09-06 | 2014-09-10 | 诺沃—诺迪斯克有限公司 | Glp-1 derivatives |
KR20130049671A (en) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | Method for preparation of biological active polypeptide conjugate |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
US20150038417A1 (en) | 2011-12-09 | 2015-02-05 | Novo Nordisk A/S | GLP-1 Agonists |
KR101895047B1 (en) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | A site-specific GLP-2 conjugate using an immunoglobulin fragment |
BR112014018575A2 (en) | 2012-01-26 | 2017-07-04 | Amgen Inc | Growth Differentiation Factor 15 Polypeptides (gdf-15) |
AR090281A1 (en) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX |
CA2861592A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
RS57727B1 (en) | 2012-03-22 | 2018-12-31 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
WO2013171570A1 (en) | 2012-05-16 | 2013-11-21 | Glaxo Group Limited | Polypeptide loaded poca nanoparticles for oral administration |
CN107739409A (en) * | 2012-05-18 | 2018-02-27 | 爱德迪安(北京)生物技术有限公司 | Albumen, protein conjugate and its application for treating diabetes |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
CA2869674A1 (en) | 2012-06-08 | 2013-12-12 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
ES2871328T3 (en) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Tablet formulation comprising a peptide and a delivery agent |
IN2015DN01115A (en) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
AR094821A1 (en) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION |
AR092862A1 (en) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD |
AR091902A1 (en) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
WO2014072481A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
KR102202255B1 (en) | 2012-11-20 | 2021-01-13 | 옵코 바이오로직스 리미티드 | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
KR20150096433A (en) | 2012-12-21 | 2015-08-24 | 사노피 | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
CA2896793A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
CN104277112B (en) * | 2013-07-04 | 2018-01-26 | 嘉和生物药业有限公司 | Long-acting hypoglycemic fusion protein |
KR102376451B1 (en) | 2013-07-31 | 2022-03-23 | 암젠 인크 | Growth differentiation factor 15 (gdf-15) constructs |
CN103408669B (en) * | 2013-08-01 | 2016-01-20 | 江苏泰康生物医药有限公司 | GLP-1 analog fusion, and its production and use |
CN104371019B (en) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1 |
EP3033355A1 (en) * | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
EP3054973B1 (en) | 2013-10-10 | 2020-12-02 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
JP2017501970A (en) * | 2013-12-10 | 2017-01-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Use of subunit binding domains of multi-subunit structures for target-specific delivery of pharmaceutically active entities to multi-subunit structures |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
WO2015165480A1 (en) | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
NO2776305T3 (en) | 2014-04-23 | 2018-01-27 | ||
ES2818824T3 (en) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Compositions comprising a VIP-ELP fusion protein for use in the treatment of cystic fibrosis |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
CN104558198A (en) * | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | Preparation method and application of fusion protein of GLP-1 analogue and amylin analogue |
CN104257696B (en) * | 2014-09-04 | 2017-08-25 | 西安国誉生物科技有限公司 | A kind of steady sugar yeast bacterium powder of hypoglycemic and its preparation method and application |
WO2016034186A1 (en) | 2014-09-05 | 2016-03-10 | University Of Copenhagen | Gip peptide analogues |
CN107108713A (en) * | 2014-10-10 | 2017-08-29 | 诺和诺德股份有限公司 | The stable glucagon receptor co-agonists of GLP 1/ based on GLP 1 |
CN104327187B (en) * | 2014-10-11 | 2018-06-08 | 上海兴迪金生物技术有限公司 | A kind of recombined human GLP-1-Fc fusion proteins |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
WO2016073704A1 (en) * | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
MX2017007392A (en) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Treating seizure with recombinant alkaline phosphatase. |
CA2968987C (en) * | 2014-12-08 | 2022-05-10 | 1Globe Biomedical Co., Ltd. | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
WO2016118577A1 (en) * | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
EP3250227A2 (en) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
ES2822598T3 (en) | 2015-02-09 | 2021-05-04 | Phasebio Pharmaceuticals Inc | Methods and Compositions for Treating Muscle Diseases and Disorders |
CA2975633A1 (en) | 2015-02-11 | 2016-08-18 | Gmax Biopharm Llc. | Stable pharmaceutical solution formulation of glp-1r antibody fusion protein |
JP2018511329A (en) * | 2015-04-01 | 2018-04-26 | ザ スクリプス リサーチ インスティテュート | Methods and compositions related to GPCR agonist polypeptides |
TN2017000432A1 (en) | 2015-04-10 | 2019-04-12 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
AR105616A1 (en) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | FUSION PROTEINS |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
JP6823055B2 (en) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | How to treat soft meningeal carcinomatosis |
ES2893616T3 (en) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Long-acting coagulation factors and methods for their production |
AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
RU2745528C2 (en) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Production of alkaline phosphatases |
EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
AU2016315889A1 (en) | 2015-09-04 | 2018-03-22 | The California Institute For Biomedical Research | Insulin immunoglobulin fusion proteins |
US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
JP2018533571A (en) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Methods for treating cranial suture early healing disease in a patient |
CN105367664B (en) * | 2015-11-04 | 2019-09-20 | 成都贝爱特生物科技有限公司 | Activate GLP-1 receptor and the preparation of the fusion protein of the difunctional effect of Amylin receptor and application thereof |
EP3967707A1 (en) * | 2015-11-16 | 2022-03-16 | Ubiprotein, Corp. | A method for extending half-life of a protein |
EP3925969A1 (en) | 2015-11-24 | 2021-12-22 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
RU2754558C2 (en) | 2016-04-01 | 2021-09-03 | Алексион Фармасьютикалз, Инк. | Treatment of muscular weakness with alkaline phosphatases |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
CN109071634A (en) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | Antibody coupling matter and its preparation and application |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
SG10202100189WA (en) | 2016-07-11 | 2021-02-25 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
CN106046176B (en) * | 2016-08-16 | 2019-09-10 | 中国药科大学 | A kind of high active long-acting hypoglycemic fusion protein and preparation method thereof and medical usage |
JP7018933B2 (en) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | How to treat bronchomalacia |
CN106279400A (en) * | 2016-09-06 | 2017-01-04 | 中国药科大学 | Design of P8 incretin peptide and application thereof |
WO2018045872A1 (en) * | 2016-09-06 | 2018-03-15 | 中国药科大学 | Polypeptide and uses thereof |
CN109200273B (en) * | 2017-07-04 | 2021-02-19 | 中国药科大学 | Application of polypeptide in preparation of medicine for preventing or treating fatty liver disease |
CN110582302A (en) * | 2016-12-14 | 2019-12-17 | 利甘达尔股份有限公司 | Compositions and methods for nucleic acid and/or protein payload delivery |
CN106519016A (en) * | 2016-12-20 | 2017-03-22 | 中国药科大学 | Design and application of blood glucose reducing and lipid regulating peptide Progly |
CN107033234B (en) * | 2017-01-03 | 2018-06-26 | 北京凯因科技股份有限公司 | Acylated glp-1 derivatives |
EP3574004A1 (en) * | 2017-01-25 | 2019-12-04 | Medimmune, LLC | Relaxin fusion polypeptides and uses thereof |
KR20190129058A (en) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | How to treat hypophosphatase (HPP) in adults and adolescents |
CN108727486A (en) * | 2017-04-24 | 2018-11-02 | 舒泰神(北京)生物制药股份有限公司 | Long-acting nerve growth factor, preparation method and combinations thereof |
AU2018273406A1 (en) | 2017-05-24 | 2020-01-16 | Transfert Plus, S.E.C. | Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases |
JP2020521784A (en) | 2017-05-31 | 2020-07-27 | ユニバーシティ オブ コペンハーゲン | Long-acting GIP peptide analogues |
PL3474820T3 (en) | 2017-08-24 | 2024-05-13 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
EP3713593A2 (en) | 2017-11-21 | 2020-09-30 | Eli Lilly and Company | Methods of using and compositions containing dulaglutide |
CN115109166A (en) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | Multi-domain active protein for treating metabolic diseases |
CN116143939A (en) * | 2017-11-24 | 2023-05-23 | 浙江道尔生物科技有限公司 | Multiple active protein for treating metabolic diseases |
CN111518770B (en) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | Stem cell for expressing GLP1 and FGF21 and application thereof |
CN113603794B (en) * | 2018-01-11 | 2024-01-16 | 安源医药科技(上海)有限公司 | Synergistic bifunctional proteins for regulating blood glucose and lipids |
WO2019140021A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
CN110092835A (en) * | 2018-01-30 | 2019-08-06 | 上海惠盾生物技术有限公司 | A kind of GLP-1 analog-COL3A1 fusion protein |
BR112020014624A2 (en) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT) |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
DK3774862T3 (en) | 2018-04-05 | 2022-09-05 | Sun Pharmaceutical Ind Ltd | New GLP-1 analogs |
CR20200510A (en) | 2018-04-09 | 2020-11-26 | Amgen Inc | Growth differentiation factor 15 fusion proteins |
WO2019200594A1 (en) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | Acylated glp-1 derivative |
CN110964116A (en) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc fusion proteins and conjugates thereof |
EA202191105A1 (en) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | FUSION PROTEINS OBTAINED FROM GLUCAGON-LIKE PEPTIDE 1 (GLP1) AND GROWTH DIFFERENTIATION FACTOR 15 (GDF15) AND THEIR APPLICATION |
CA3121043A1 (en) | 2018-12-03 | 2020-06-11 | Antag Therapeutics Aps | Modified gip peptide analogues |
WO2020118843A1 (en) * | 2018-12-12 | 2020-06-18 | 四川利通科创生物医药科技有限公司 | Glp-1 mutant, preparation method and application thereof |
TW202024134A (en) | 2018-12-21 | 2020-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | A bispecific protein |
CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
CN110151980B (en) * | 2019-06-30 | 2022-12-09 | 中国药科大学 | Application of GLP-1 receptor agonist fusion protein in preparation of medicine for preventing or treating hyperlipidemia |
KR20220143037A (en) | 2020-02-18 | 2022-10-24 | 노보 노르디스크 에이/에스 | GLP-1 compositions and uses thereof |
AU2021224412A1 (en) | 2020-02-22 | 2022-09-15 | Jcr Pharmaceuticals Co., Ltd. | Human transferrin receptor binding peptide |
CN115925994B (en) * | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | Polypeptide conjugates and methods of use |
EP4317174A1 (en) | 2021-03-22 | 2024-02-07 | Peptiaid Inc | Peptide and peptide-containing composition |
TW202305012A (en) | 2021-03-22 | 2023-02-01 | 日商肽夢想股份有限公司 | c-Met protein-binding peptide complex |
CN113150172B (en) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | GLP-1R/GIPR double-target agonist fusion protein and preparation method and application thereof |
CA3222510A1 (en) | 2021-06-18 | 2022-12-22 | Peptidream Inc. | Ghr-binding pending peptide and composition comprising same |
AU2022329794A1 (en) | 2021-08-19 | 2024-02-22 | Jcr Pharmaceuticals Co., Ltd. | Human transferrin receptor–binding peptide |
JPWO2023026994A1 (en) | 2021-08-21 | 2023-03-02 | ||
WO2023027125A1 (en) | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | Human transferrin receptor-binding antibody-peptide conjugate |
AU2022355276A1 (en) | 2021-09-30 | 2024-05-16 | Peptidream Inc. | Peptide |
CN113801853B (en) * | 2021-11-19 | 2022-03-15 | 山东兴瑞生物科技有限公司 | Exendin-4 fusion gene modified MSC and application thereof |
WO2023179796A1 (en) * | 2022-03-25 | 2023-09-28 | Beijing Ql Biopharmaceutical Co., Ltd. | Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof |
CN116848243B (en) * | 2022-03-30 | 2024-03-19 | 北京质肽生物医药科技有限公司 | Liquid pharmaceutical compositions of polypeptide conjugates and methods of use thereof |
CN114774496B (en) * | 2022-06-21 | 2022-10-04 | 北京惠之衡生物科技有限公司 | Method for preparing GLP-1 analogue through high-density fermentation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069911A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
ATE92107T1 (en) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS. |
FR2650598B1 (en) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
FR2686900B1 (en) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
BR9507505A (en) * | 1994-04-22 | 1997-09-02 | Corixa Corp | Isolated dna molecule recombinant host cell expression vector method for preparing a polypeptide that stimulates a th1 immune response in peripheral blood mononuclear cells obtained from an individual infected with leishmania polypeptide method to assess a patient's ability to generate an immune response method to improve a cellular and / or humoral immune response to a patient's antigen method to stimulate antibody production in a |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
PE99498A1 (en) | 1996-07-26 | 1999-01-21 | Novartis Ag | FUSION POLYPEPTIDES |
EP2016950B1 (en) | 1996-08-08 | 2011-01-05 | Amylin Pharmaceuticals, Inc. | Pharmaceutical composition comprising an exendin-4 peptide |
UA72181C2 (en) * | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Derivatives of glucanolike peptide-1 |
UA65549C2 (en) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
US6190909B1 (en) * | 1997-04-17 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | TH2-specific gene |
EP0887061A1 (en) * | 1997-06-28 | 1998-12-30 | The Procter & Gamble Company | Faecal collector |
NZ502592A (en) | 1997-08-08 | 2002-03-28 | Amylin Pharmaceuticals Inc | Exendin agonist peptides and their use in the treatment of type I and II diabetes |
DK1032587T4 (en) | 1997-11-14 | 2013-04-08 | Amylin Pharmaceuticals Llc | New exendin agonist compounds |
NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
ES2291017T3 (en) | 1998-02-13 | 2008-02-16 | Amylin Pharmaceuticals, Inc. | INOTROPIC AND DIURETIC EFFECTS OF EXENDINE AND GLP-1. |
AU2610799A (en) * | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates |
JP2002506792A (en) * | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | N-terminal modified GLP-1 derivative |
WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
ATE466027T1 (en) * | 1998-02-27 | 2010-05-15 | Novo Nordisk As | DERIVATIVES OF GLP-1 ANALOGUE |
DK1088084T3 (en) * | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-human serum albumin fusion protein |
WO2000034784A1 (en) * | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
DK1463751T3 (en) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albumin Fusion Proteins. |
WO2003059934A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
-
2001
- 2001-11-29 SI SI200130878T patent/SI1355942T1/en unknown
- 2001-11-29 UA UAA200706704A patent/UA93662C2/en unknown
- 2001-11-29 SI SI200130945T patent/SI1724284T1/en unknown
- 2001-11-29 DK DK01995845T patent/DK1355942T3/en active
- 2001-11-29 BR BR0116024-9A patent/BR0116024A/en not_active Application Discontinuation
- 2001-11-29 CZ CZ2014-740A patent/CZ308214B6/en not_active IP Right Cessation
- 2001-11-29 DE DE60139430T patent/DE60139430D1/en not_active Expired - Lifetime
- 2001-11-29 MX MXPA03005036A patent/MXPA03005036A/en active IP Right Grant
- 2001-11-29 PL PL393178A patent/PL393178A1/en unknown
- 2001-11-29 PT PT06118975T patent/PT1724284E/en unknown
- 2001-11-29 EP EP01995845A patent/EP1355942B1/en not_active Expired - Lifetime
- 2001-11-29 PL PL366208A patent/PL209550B1/en unknown
- 2001-11-29 DE DE60135581T patent/DE60135581D1/en not_active Expired - Lifetime
- 2001-11-29 AT AT06118975T patent/ATE437891T1/en active
- 2001-11-29 CA CA2434237A patent/CA2434237C/en not_active Expired - Lifetime
- 2001-11-29 AU AU2002226897A patent/AU2002226897B2/en not_active Expired
- 2001-11-29 SK SK50057-2011A patent/SK288088B6/en not_active IP Right Cessation
- 2001-11-29 KR KR1020037007541A patent/KR100942864B1/en active IP Right Grant
- 2001-11-29 CN CNA018202322A patent/CN1483041A/en active Pending
- 2001-11-29 WO PCT/US2001/043165 patent/WO2002046227A2/en active Application Filing
- 2001-11-29 UA UA2003065280A patent/UA81897C2/en unknown
- 2001-11-29 AU AU2689702A patent/AU2689702A/en active Pending
- 2001-11-29 EP EP06118975A patent/EP1724284B1/en not_active Expired - Lifetime
- 2001-11-29 AT AT01995845T patent/ATE406384T1/en active
- 2001-11-29 HU HU1300326A patent/HU230603B1/en unknown
- 2001-11-29 CA CA2716959A patent/CA2716959A1/en not_active Abandoned
- 2001-11-29 DK DK06118975T patent/DK1724284T3/en active
- 2001-11-29 JP JP2002547963A patent/JP2004528014A/en active Pending
- 2001-11-29 ES ES01995845T patent/ES2311560T3/en not_active Expired - Lifetime
- 2001-11-29 US US10/433,108 patent/US7271149B2/en not_active Expired - Lifetime
- 2001-11-29 KR KR1020087019148A patent/KR20080085082A/en not_active Application Discontinuation
- 2001-11-29 PT PT01995845T patent/PT1355942E/en unknown
- 2001-11-29 HU HU0302529A patent/HU229218B1/en unknown
- 2001-11-29 CN CN200910173888A patent/CN101712722A/en active Pending
- 2001-11-29 ES ES06118975T patent/ES2328510T3/en not_active Expired - Lifetime
- 2001-11-29 NZ NZ525577A patent/NZ525577A/en not_active IP Right Cessation
- 2001-11-29 SK SK670-2003A patent/SK288342B6/en not_active IP Right Cessation
- 2001-11-29 EA EA200300644A patent/EA005584B1/en not_active IP Right Cessation
- 2001-11-29 CZ CZ2003-1602A patent/CZ306180B6/en not_active IP Right Cessation
- 2001-11-29 IL IL15581201A patent/IL155812A0/en unknown
-
2003
- 2003-05-08 IL IL155812A patent/IL155812A/en not_active IP Right Cessation
- 2003-05-12 ZA ZA200303642A patent/ZA200303642B/en unknown
- 2003-06-05 NO NO20032565A patent/NO331273B1/en not_active IP Right Cessation
- 2003-06-05 HR HR20030455A patent/HRP20030455A2/en not_active Application Discontinuation
-
2004
- 2004-03-25 HK HK04102243.7A patent/HK1061411A1/en not_active IP Right Cessation
-
2006
- 2006-06-06 EC EC2006004643A patent/ECSP064643A/en unknown
-
2007
- 2007-07-05 IL IL184429A patent/IL184429A/en active IP Right Grant
-
2008
- 2008-11-06 CY CY20081101263T patent/CY1108485T1/en unknown
-
2009
- 2009-09-18 CY CY20091100966T patent/CY1109377T1/en unknown
-
2010
- 2010-08-20 JP JP2010185227A patent/JP2011006447A/en active Pending
- 2010-11-15 NO NO20101602A patent/NO20101602L/en not_active Application Discontinuation
-
2011
- 2011-10-10 NO NO20111369A patent/NO332221B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069911A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
Non-Patent Citations (1)
Title |
---|
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664 - 1669, XP002222050, ISSN: 0022-2623 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US9173950B2 (en) | 2012-05-17 | 2015-11-03 | Extend Biosciences, Inc. | Vitamin D-ghrelin conjugates |
US9289507B2 (en) | 2012-05-17 | 2016-03-22 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002046227A3 (en) | Glp-1 fusion proteins | |
AU2002322403A1 (en) | Glucagon-like peptide-1 analogs | |
WO2003058203A3 (en) | Extended glucagon-like peptide-1 analogs | |
WO2001098331A3 (en) | Glucagon-like peptide-1 analogs | |
AU2002228608A1 (en) | Amidated glucagon-like peptide-1 | |
EP2186824A3 (en) | Chronic treatment regimen using glucagon-like insulinotropic peptides | |
EP0997151A3 (en) | Method for administering insulinotropic peptides | |
HUP0204281A3 (en) | Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds | |
AU8010400A (en) | Enhancing interface to transport streams by pin re-assignment | |
WO2000069901A3 (en) | Proteins with insulin-like activity useful in the treatment of diabetes | |
AU4445201A (en) | Method for administering insulin to the buccal region | |
AU2205099A (en) | Chimeric proteins for the treatment of diabetes | |
WO2003020759A3 (en) | A caspase- 8 binding protein, its preparation and use | |
MXPA01011719A (en) | A somatotropin composition with improved syringeability. | |
AU2002215734A1 (en) | Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus | |
WO2001085908A9 (en) | Clasp-1 transmembrane protein | |
AU9363301A (en) | A novel polypeptide-human l1 motif-like orf2 protein 21 and the polynucleotide encoding said polypeptide | |
AU7043501A (en) | A novel polypeptide, a human protein 11 containing g protein coupling receptor conserved region and the polynucleotide encoding the polypeptide | |
WO2002050274A3 (en) | Seleno-cysteine containing protein zsel1 | |
AU2002356599A1 (en) | Production of recombinant antibodies by means of fusion with elastin-like peptides | |
AU7623901A (en) | A novel polypeptide, a human protein 9 similar to inclusin, and the polynucleotide encoding the polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 525577 Country of ref document: NZ Ref document number: 546/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 155812 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/03642 Country of ref document: ZA Ref document number: 200303642 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002226897 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433108 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6702003 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037007541 Country of ref document: KR Ref document number: P20030455A Country of ref document: HR Ref document number: PA/a/2003/005036 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018202322 Country of ref document: CN Ref document number: 1-2003-500482 Country of ref document: PH Ref document number: PV2003-1602 Country of ref document: CZ Ref document number: 1200300508 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002547963 Country of ref document: JP Ref document number: 03048706 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001995845 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434237 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300644 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001995845 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037007541 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 525577 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525577 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: PI0116024 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-1602 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 184429 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref country code: SK Ref document number: SK A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2014-740 Country of ref document: CZ |